Muller & Phipps (India) is engaged in marketing of over the counter medical preparation and home care products.Product Profile: a) Cavisan - Medicated Dental Cream b) Cavifast - Medicated Dental Cream c) Cavisan - Gum Astringent d) Nixoderm
MULLER AND PHIPPS INDIA LIMITED. C-204,2N? FLOOR, MADHAVA, BANDRA KURLA COMPLEX, MUMBAI-400 052. CIN: L63090MH1917PLC007897 September 07, 2026 The Secretary, Bombay Stock Exchange Limited, 1st Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai —400001 Scrip Code: 501477 Dear Sir, Sub: Compliance under Regulation 47 of the SEBI (Listing Obligations & Disclosure...
Muller and Phipps India Limited has announced the publication of its unaudited financial results for the quarter ended June 30, 2026. The company reported a total income of 203.33, alongside a net loss of 10.02 for the quarter. This translates to diluted earnings per share of 0.00. These financial figures...
Muller and Phipps India Limited confirmed the proper handling of share dematerialization requests for the quarter ended June 30, 2026. The company's Registrar and Share Transfer Agent verified that all securities received for dematerialization were processed, confirmed, and listed on stock exchanges. Physical certificates were cancelled, and the company's register...
Muller & Phipps (India) Ltd's Board, in a meeting, approved the audited financial results for the quarter and year ended March 31, 2026. For the year, total income from operations was Rs 6.91 Cr. The company reported a net loss of Rs 0.03 Cr for the year, with a basic...
Muller and Phipps India Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, prepared by a Practicing Company Secretary, confirms the company's overall compliance with SEBI regulations and good corporate governance practices. A temporary technical issue with the company's website prevented...
